STAT+: AstraZeneca’s experimental COPD treatment posts strong results in late-stage studies — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Tozorakimab reduced COPD exacerbations by approximately 30% across all patients over a year in two Phase 3 trials, with data presented at the European Respiratory Society's annual conference in Barcelona and published in the New England Journal of Medicine.
- AstraZeneca could capture a large market segment because the tozo trials enrolled COPD patients ineligible for other recently approved treatments.
- Analysts and AstraZeneca project tozorakimab could generate billions in annual sales if approved, with potential applications beyond COPD including asthma.
- COPD ranks as the third-leading cause of death globally and remains a greatly underserved condition.
- AstraZeneca views the results as a reassuring victory after recent notable trial misses, most dramatically with a heart disease drug.
Why it matters: For the roughly 30% of trial patients whose exacerbations were prevented over a year, tozorakimab could become a needed new option in a condition that ranks as the world's third-leading cause of death. AstraZeneca, coming off a dramatic heart-drug miss, regains trial momentum in respiratory care with a product analysts project could earn billions — particularly by reaching COPD patients whom competing newer therapies exclude.
Ask SkimNews
